The importance of human data in the establishment of occupational exposure limits

Human and Ecological Risk Assessment

Volumn 8, Issue 4, 2002, Pages 805-822

  Sargent, Edward V ^a   Naumann, Bruce D ^a   Dolan, David G ^a   Faria, Ellen C ^a   Schulman, Lisa ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

Human data; Occupational exposure limits; Risk assessment

Indexed keywords

ANIMALIA;

EID: 22344454413     PISSN: 10807039     EISSN: None     Source Type: Journal    
DOI: 10.1080/10807030290879961     Document Type: Article

References (64)

1. th edit, vol I. Cincinnati, OH, USA
2. AHFS (American Hospital Formulary Service). 2000. American Hospital Formulary Service - Drug Information, pp 1625-28. American Society of Health-System Pharmacists, Inc, Bethesda, MD, USA
3. AHFS (American Hospital Formulary Service). 2001. American Hospital Formulary Service Drug Information. American Society of Health-System Pharmacists, Bethesda, MD, USA
4. Beall JR and Klein MF. 1977. Enhancement of aspirin-induced teratogenicity by food restriction in rats. Tox Appl Pharm 39:489
5. Bhat R, Vidyasagar D, Fisher E, et al. 1980. Pharmacokinetics of oral and intravenous indomethacin in preterm infants. Dev Pharmacol Ther 1(2-3):101-10
6. Bryant MF, Erexson GL, and Kligerman AD. 1989. A comparison of sister-chromatid exchange in mouse peripheral blood lymphocytes exposed in vitro and in vivo to phosphoramide mustard and 4-hydroxycyclophosphamide. Mutat Res 222:271-7
7. Canner PL, Berge KB, Wenger NK, et al. 1986. Cooperative studies: Fifteen year mortality in coronary drug project patients: long term benefit with niacin. J Am Coll Cardiol 8:1245-55
8. Carlson LA and Rosenhamer G. 1988. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scan 223:405-18
9. Cattley RC and Glover SE. 1993. Elevated 8-hydroxydeoxyguanosine in hepatic DNA of rats following exposure to peroxisome proliferators: relationship to carcinogenesis and nuclear localization. Carcinogenesis 14:2495-9
10. th edit, chap 51, pp 12330-1287. McGraw-Hill, NY, NY, USA
11. CPI (Committee of Principal Investigators). 1978. A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 40:1069-118
12. CPI (Committee of Principal Investigators). 1980. WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet ii:379-85
13. CPI (Committee of Principal Investigators). 1984. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet ii:600-4
14. Corton JC, Anderson SP, and Stauber A. 2000. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Ann Rev Pharmacol Toxicol 40:491-518
15. Davis DP, Daston GP, Odio MR, et al. 1996. Maternal reproductive effects of oral salicylic acid in Sprague-Dawley rats. Toxicol Lett 84:135-41
16. Diener RM, and Hsu B. 1966. Effects of certain aryloxisobutyrates on the rat fetus. Toxicol Appl Pharmacol 8:338
17. Dourson ML, Anderson ME, Erdreich LS, et al. 2001. Using human data to protect the public's health. Reg Tox Pharmacol 33:234-56
18. Farrell B, Heineman J, et al. 1995. Low dose aspirin in pregnancy and early childhood development-follow up of the collaborative low dose aspirin study in pregnancy. Br J Obstet Gynaecol 102:861-8
19. Garcia-Rodrieguez LA and Huerta-Alvarez C. 2001. Reduced risk of colorectal cancer among long term users of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. Epidemiology 12:88-93
20. Greaves P, Irisami E, and Monro AM. 1986. Hepatic foci of cellular and enzymatic alteration and nodules in rats treated with clofibrate or diethylnitrosamine followed by phenobarbital: their rate of onset and their reversibility. J Natl Cancer Inst 76:475-84
21. Hanefeld M, Kemmer C, Leonhardt W, et al. 1980. Effects of p-chlorophenoxyisobutyric acid (CPIB) on the human liver. Atherosclerosis 26:159-72
22. Hanefeld M, Kemmer C, and Kadner E. 1983. Relationship between morphological changes and lipid-lowering action of p-chlorophenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Atherosclerosis 46:239-46
23. Heyman MA and Rudolph AM. 1976. Effects of acetyl salicylic acid on the ductus arteriosus and circulation in fetal lamb in utero. Circ Res 38:418-22
24. HSDB (Hazardous Substance Data Bank). 2001. Acetyl salicylic acid. National Library of Medicine, Bethesda, MD, USA. Micromedex, Inc, Englewood, CO, USA
25. IARC (International Agency for Research on Cancer). 1980. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, vol 24, pp 39-58. Some Pharmaceutical Drugs. Lyon, France
26. IARC (International Agency for Research on Cancer). 1981. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, vol 9, pp 165-202. Cyclophosphamide. Lyon, France
27. IARC (International Agency for Research on Cancer). 1983. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Some Food Additives, Feed Additives and Naturally Occurring Substances, vol 31, pp 95-132. Lyon, France
28. IARC (International Agency for Research on Cancer). 1996. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Some Pharmaceutical Drugs, vol 66, pp 391-426. Lyon, France
29. Igarashi T. 1994. The duration of toxicity studies required to support repeated dosing in clinical investigation - A toxicologist's opinion. In: Parkinson E, McAuslane N, Lumley C, et al., eds., CMR Workshop: The Timing of Toxicological Studies to Support Clinical Trials, pp 67-74. Kluwer, Boston, USA
30. th edit, pp 617-57. McGraw-Hill, NY, NY, USA
31. Jasiewicz ML and Richardson JC. 1987. Absence of mutagenic activity of benorylate, paracetamol and aspirin in the Salmonella/mammalian microsome test. Mutation Res 190:95-100
32. Kelly JP and Kaufman DW. 1996. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered products. Lancet 348:413-1421
33. Kimmel CA, Wilson JG, and Schumacher HJ. 1971. Studies on the metabolism and identification of the causative agent in aspirin teratogenesis and behavioral changes in rats. Teratology 10:293
34. Lione A and Scialli AR. 1995. The developmental toxicity of indomethacin and sulindac. Reprod Toxicol 9(1):7-20
35. Lumley CE. 1990. Clinical toxicity: Could it have been prevented? Premarketing experience. In: Lumley CE and Walker SW, eds, Lancaster CMR Workshop - Animal Toxicity Studies: Their Relevance for Man, pp 49-56
36. Marsman DS, Goldsworthy TL, and Popp JA. 1992. Contrasting hepatocytic peroxisome proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens. Wy-14,643 and clofibric acid. Carcinogenesis 13:1011-7
37. McClure HM, Wilk AL, Horigan EA, et al. 1979. Induction of craniofacial malformations in rhesus monkeys (Macaca mulatta) with cyclophosphamide. Cleft Palate J 16:248-56
38. McConnell EE. 2000. The value and ethics of using human data for the registration of pesticides. The_Toxicologist 54:411
39. th Edition). Montvale, NJ, USA
40. th Edition ed). Montvale, NJ, USA
41. Moise KJJr, Ou C-N, and Kirshon B. 1990. Placental transfer of indomethacin in the human pregnancy. Am J Obstet Gynecol 162:549-54
42. Momma K and Takao A. 1990. Transplacental cardiovascular effects of four popular analgesics in rats. Am J Obstet Gynecol 162:1304-10
43. Moore FR, Urda GA, Krishna G, et al. 1995. An in vivo/in vitro method for assessing micronucleus and chromosome aberration induction in rat bone marrow and spleen 1. Studies with cyclophosphamide. Mutat Res 335:191-9
44. Nyitray M, Szaszovszky E, and Druga A. 1980. Clofibrate and the development of rats. Arch Toxicol Suppl 4:463-5
45. Olson H, Betton G, Robinson D, et al. 2000. Concordance of the toxicity of pharmaceuticals in humans and in animals. Reg Tox Pharmacol 32:56-67
46. Qiu J, Hales BF, and Robaire B. 1995. Damage to rat spermatozoal DNA after chronic cyclophosphamide exposure. Biol Reprod 53:1465-73
47. Rane A, Oelz O, Frolich JC, et al. 1978. Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clin Pharmacol Ther 23(6):658-68
48. Reddy JK and Qureshi SA. 1979. Tumorigenicity of the hypolipidaemic peroxisome proliferator ethyl-a-p-chlorophenoxyisobutyrate (clofibrate) in rats. Br J Cancer 40:476-82
49. Reprotox System. 2001. Micromedex, Inc., Englewood, CO, USA
50. Schardein JL and Scialli AR. 1999. The legislation of toxicological safety factors: the Food Quality Protection Act with chlorpyrifos as a test case. Reprod Toxicol 13(1):1-14
51. Schmahl D and Habs M. 1979. Carcinogenic action of low-dose cyclophosphamide given orally to Sprague-Dawley rats in a lifetime experiment. Int J Cancer 23:706-12
52. Schulman LJ, Sargent EV, Naumann BD, et al. 2002. A human health risk assessment of pharmaceuticals in the aquatic environment. Human Ecol Risk Assess (accepted for publication)
53. Sessink PJM, Froes ED, van Kranen HJ, et al. 1995. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health 67:317-23
54. th ed., pp 159-61. The Johns Hopkins University Press, Baltimore, MD, USA
55. State of California. 1993. Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65). No Significant Risk Levels for Carcinogens and Acceptable Intake Levels for Reproductive Toxicants (Status Report). 22 Cal. Code of Reg. Section 12705(d). August
56. Svoboda DJ and Azarnoff DL. 1979. Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug. Cancer Res 39:3419-3428
57. Tanaka K, Smith PF, Stromberg PC, et al. 1992. Studies of early hepatocellular proliferation and peroxisomal proliferation in Sprague-Dawley rats treated with tumorigenic doses of clofibrate. Toxicol Appl Pharmacol 116:71-7
58. Trasler DG. 1965. Aspirin-induced cleft lip and other malformations in mice. The Lancet 606-7
59. Tucker MJ and Orton TC. 1995. Comparative Toxicology of Hypolipdaemic Fibrates, pp 1-22. Taylor and Francis, London, UK
60. USEPA (U.S. Environmental Protection Agency). 1996. Proposed Guidelines for Carcinogen Risk Assessment. Fed Reg 61:17960-8011
61. van Overmeire B, Brus F, van Acker KJ, et al. 1995. Aspirin versus indomethacin treatment of patent ductuc arteriosus in preterm infants with respiratory distress syndrome. Pediatr Res 38(6):886-91
62. Verbesselt R, Tjandramaga TB, Mullie A, et al. 1983. Comparative multiple dose kinetics of two formulations of indomethacin. Eur J Clin Pharmacol 24 (4):563-8
63. Waltman R, Tricomi V, Shabanah EH, et al. 1973. The effect of anti-inflammatory drugs on parturition parameters in the rat. Prostaglandins 4:93-106
64. Wilson GN, King T, Argyle JC, et al. 1991. Maternal clofibrate administration amplifies fetal peroxisomes. Pediatr Res 29:256-62